Restricted accessResearch articleFirst published online 2024-12
Reporting of comorbidities and health status of participants in clinical trials testing amyloid- and tau-targeting monoclonal antibodies for Alzheimer's disease: A systematic review
Controversies exist around the external validity of clinical trials on disease-modifying treatments for Alzheimer's disease (AD). Detailed information on the clinical characteristics of research participants is lacking, hampering the understanding of their representativeness.
Objective
This study aimed to systematically review the baseline comorbidities and health status of patients with AD enrolled in clinical trials.
Methods
A systematic review of scientific and gray literature was conducted. Randomized controlled trials, enrolling participants in the AD continuum, and testing amyloid- and tau-targeting monoclonal antibodies were selected. Data on the type of study and intervention and the baseline clinical characteristics of participants were extracted. The proportion of studies reporting information on comorbidities, integrative measures of health (e.g., number of chronic diseases and multimorbidity, frailty, and gait speed), and non-neurological concomitant therapies of participants was calculated.
Results
Thirty-six articles, referring to 41 studies (21,952 participants) were included. None of the retained trials provided information on the comorbidities or other integrative measures reflecting the baseline health status of participants. Only three studies reported data on non-neurological concomitant therapies. Five documents providing relevant information were identified through gray literature searches covering the websites of regulatory agencies and pharmaceutical manufacturers.
Conclusions
The health characteristics of patients with AD included in randomized controlled trials are poorly reported. Therefore, the external validity of the study findings cannot be fully appreciated.
WinbladBAmouyelPAndrieuS, et al.Defeating Alzheimer’s disease and other dementias: a priority for European science and society. Lancet Neurol2016; 15: 455–532.
2.
CummingsJZhouYLeeG, et al.Alzheimer’s disease drug development pipeline: 2023. Alzheimers Dement (N Y)2023; 9: e12385.
WideraEWBrangmanSAChinNA. Ushering in a new era of Alzheimer disease therapy. JAMA2023; 330: 503–504.
7.
MullardA. Landmark Alzheimer’s drug approval confounds research community. Nature2021; 594: 309–310.
8.
ThambisettyMHowardR. Lecanemab trial in AD brings hope but requires greater clarity. Nat Rev Neurol2023; 19: 132–133.
9.
RosenthalMB. Novel Alzheimer disease treatments and reconsideration of US pharmaceutical reimbursement policy. JAMA2023; 330: 505–506.
10.
RothwellPM. External validity of randomised controlled trials: ‘to whom do the results of this trial apply?’. Lancet2005; 365: 82–93.
11.
FranzenSSmithJEvan den BergE, et al.Diversity in Alzheimer’s disease drug trials: the importance of eligibility criteria. Alzheimers Dement2022; 18: 810–823.
12.
MartinkovaJQuevencoF-CKarcherH, et al.Proportion of women and reporting of outcomes by sex in clinical trials for Alzheimer disease: a systematic review and meta-analysis. JAMA Network Open2021; 4: e2124124.
13.
Arce RenteríaMMobleyTMEvangelistaND, et al.Representativeness of samples enrolled in Alzheimer’s disease research centers. Alzheimers Dement (Amst)2023; 15: e12450.
14.
AndersonTSAyanianJZSouzaJ, et al.Representativeness of participants eligible to be enrolled in clinical trials of aducanumab for Alzheimer disease compared with medicare beneficiaries with Alzheimer disease and mild cognitive impairment. JAMA2021; 326: 1627–1629.
15.
CanevelliMRossiPDAstroneP, et al.‘Real world’ eligibility for aducanumab. J Am Geriatr Soc2021; 69: 2995–2998.
16.
PittockRRAakreJCastilloAM, et al.Eligibility for anti-amyloid treatment in a population-based study of cognitive aging. Neurology2023; 101: e1837–e1849.
17.
TanYYPapezVChangWH, et al.Comparing clinical trial population representativeness to real-world populations: an external validity analysis encompassing 43 895 trials and 5 685 738 individuals across 989 unique drugs and 286 conditions in England. Lancet Healthy Longev2022; 3: e674–e689.
18.
SmithTMaidmentIHebdingJ, et al.Systematic review investigating the reporting of comorbidities and medication in randomized controlled trials of people with dementia. Age Ageing2014; 43: 868–872.
19.
CanevelliMBrunoGVanacoreN, et al.Are we really tackling the ‘evidence-based medicine issue’ in Alzheimer’s disease?Eur J Intern Med2016; 35: e29–e30.
20.
CanevelliMTrebbastoniAQuarataF, et al.External validity of randomized controlled trials on Alzheimer’s disease: the biases of frailty and biological aging. Front Neurol2017; 8: 628.
21.
WightmanHQuinnTJMairFS, et al.Frailty in randomised controlled trials for dementia or mild cognitive impairment measured via the frailty index: prevalence and prediction of serious adverse events and attrition. Alzheimers Res Ther2023; 15: 110.
22.
GrandeGMarengoniAVetranoDL, et al.Multimorbidity burden and dementia risk in older adults: the role of inflammation and genetics. Alzheimers Dement2021; 17: 768–776.
23.
GrandeGTrioloFNuaraA, et al.Measuring gait speed to better identify prodromal dementia. Exp Gerontol2019; 124: 110625.
24.
WardDDWallaceLMKRockwoodK. Cumulative health deficits, APOE genotype, and risk for later-life mild cognitive impairment and dementia. J Neurol Neurosurg Psychiatry2021; 92: 136–142.
25.
HigginsJPTThomasJChandlerJ, et al.Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022)., https://training.cochrane.org/handbook (2022, accessed 12 June 2023).
26.
PageMJMcKenzieJEBossuytPM, et al.The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ2021; 372: n71.
27.
LacorteEAncidoniAZaccariaV, et al.Safety and efficacy of monoclonal antibodies for Alzheimer’s disease: a systematic review and meta-analysis of published and unpublished clinical trials. J Alzheimers Dis2022; 87: 101–129.
28.
AvgerinosKIFerrucciLKapogiannisD. Effects of monoclonal antibodies against amyloid-β on clinical and biomarker outcomes and adverse event risks: a systematic review and meta-analysis of phase III RCTs in Alzheimer’s disease. Ageing Res Rev2021; 68: 101339.
29.
AlbertMSDeKoskySTDicksonD, et al.The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the national institute on aging-Alzheimer’s association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement2011; 7: 270–279.
30.
McKhannGMKnopmanDSChertkowH, et al.The diagnosis of dementia due to Alzheimer’s disease: recommendations from the national institute on aging-Alzheimer’s association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement2011; 7: 263–269.
31.
DuboisBFeldmanHHJacovaC, et al.Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol2007; 6: 734–746.
32.
StudenskiSPereraSPatelK, et al.Gait speed and survival in older adults. JAMA2011; 305: 50–58.
33.
HigginsJPTAltmanDGGøtzschePC, et al.The cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ2011; 343: d5928.
34.
AndjelkovicMAbi-SaabDDelmarP, et al.[P1–048]: relationship between vascular pathology at baseline and amyloid-related imaging abnormalities (ARIA) in prodromal AD patient population in scarlet road study. Alzheimers Dement2017; 13: P254.
OstrowitzkiSLasserRADorflingerE, et al.A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease. Alzheimers Res Ther2017; 9: 95.
40.
DelnomdedieuMDuvvuriSLiDJ, et al.First-In-Human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to moderate Alzheimer’s disease. Alzheimers Res Ther2016; 8: 12.
41.
AraiHUmemuraKIchimiyaY, et al.Safety and pharmacokinetics of bapineuzumab in a single ascending-dose study in Japanese patients with mild to moderate Alzheimer’s disease. Geriatr Gerontol Int2016; 16: 644–650.
42.
BlackRSSperlingRASafirsteinB, et al.A single ascending dose study of bapineuzumab in patients with Alzheimer disease. Alzheimer Dis Assoc Disord2010; 24: 198.
43.
BoydCMVollenweiderDPuhanMA. Informing evidence-based decision-making for patients with comorbidity: availability of necessary information in clinical trials for chronic diseases. PLoS One2012; 7: e41601.
44.
MoherDHopewellSSchulzKF, et al.CONSORT 2010 Explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ2010; 340: c869.
45.
LiuKYVillainNAytonS, et al.Key questions for the evaluation of anti-amyloid immunotherapies for Alzheimer’s disease. Brain Commun2023; 5: fcad175.
46.
LanctôtKLHviid Hahn-PedersenJEichingerCS, et al.Burden of illness in people with Alzheimer’s disease: a systematic review of epidemiology, comorbidities and mortality. J Prev Alzheimers Dis2024; 11: 97–107.
47.
HanlonPHanniganLRodriguez-PerezJ, et al.Representation of people with comorbidity and multimorbidity in clinical trials of novel drug therapies: an individual-level participant data analysis. BMC Med2019; 17: 201.
48.
MitchellSLMorVHarrisonJ, et al.Embedded pragmatic trials in dementia care: realizing the vision of the NIA IMPACT collaboratory. J Am Geriatr Soc2020; 68: S1–S7.
49.
Food and Drug Administration. Full prescribing information for ADUHELM. Revised June 2021.
50.
CummingsJRabinoviciGDAtriA, et al.Aducanumab: appropriate use recommendations update. J Prev Alzheimers Dis2022; 9: 221–230.
51.
CummingsJApostolovaLRabinoviciGD, et al.Lecanemab: appropriate use recommendations. J Prev Alzheimers Dis2023; 10: 362–377.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
